With $500 million in funding and a reported $2.5 billion valuation, Flourish wants to reinvent AI by putting real neurons ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Recursion (RXRX). The reason why I want to go over this biotech next is because the company ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Elon Musk's social network X (formerly known as Twitter) last night released some of the code and architecture of its overhauled social recommendation algorithm under a permissive, enterprise-friendly ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

A2Z/ ├── Problems/ # Solved problems organized by difficulty │ ├── Easy/ # Easy level problems │ ├── Medium/ # Medium level problems │ └── Hard/ # Hard level problems │ ├── DataStructures/ # Core data ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...